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Abstract 22 
Sentinel lymph node (SLN) detection techniques have the potential to change the standard of 23 
surgical care of patients with prostate cancer. We performed a lymphatic mapping study and 24 
determined the value of fluorescence SLN detection with indocyanine green (ICG) for the 25 
detection of lymph node metastases in intermediate- and high-risk patients undergoing radical 26 
prostatectomy and extended pelvic lymph node dissection. A total of 42 patients received 27 
systematic or specific ICG injections into the prostate base, the mid-portion, the apex, the left 28 
lobe or the right lobe. We found that: 1. external and internal iliac regions encompass the 29 
majority of SLNs; 2. common iliac regions contain up to 22% of all SLNs; 3. a prostatic lobe can 30 
drain into the contralateral group of pelvic lymph nodes; 4. the fossa of Marcille also receives 31 
significant drainage. Among the 12 patients who received systematic ICG injections, 5 (42%) had 32 
a total of 29 lymph node metastases. Of these, 16 nodes were ICG-positive, yielding 55% 33 
sensitivity. The complex drainage pattern of the prostate and the low sensitivity of ICG for the 34 
detection of lymph node metastases reported in our study highlight the difficulties related to the   35 
implementation of SNL techniques in prostate cancer.   36 
 37 
Patient summary: There is controversy over how extensive lymph node dissection should be 38 
during prostatectomy. We investigated the lymphatic drainage of the prostate and whether 39 
sentinel node fluorescence techniques would be useful to detect node metastases. We found that 40 
the drainage pattern is complex and that the sentinel node technique is not able to replace 41 
extended pelvic lymph node dissection. 42 
 43 
Main text 44 
The role of pelvic lymph nodes dissection (PLND) during radical prostatectomy (RP) 45 
remains a matter of continuous debate (1). Sentinel lymph node (SLN) detection has been 46 
advanced as a potential alternative to PLND. In prostate cancer, the technique was first described 47 
using 99mtechnetium bound to a colloid (2). However, radio-guided SLN detection has not come 48 
into widespread use. The use of the fluorescent dye indocyanine green (ICG) may open the door 49 
to a broader acceptance of SLN techniques in prostate cancer surgery (3). Against this 50 
background, we provide a comprehensive description of lymphatic landing sites per anatomical 51 
region of the prostate using this SLN technique. We also evaluate the sensitivity of ICG-based 52 
fluorescence SLN detection to detect lymph node metastases in intermediate- and high-risk 53 
patients.  54 
Detailed information on patient selection and detection technique is found in 55 
Supplementary Patients and Methods. From November 2012 through September 2015, 42 56 
patients presenting with clinically localized intermediate- or high-risk prostate cancer and 57 
scheduled for RP gave written informed consent to participate in our prospective study. ICG 58 
(Pulsion Medical Systems, Feldkirchen, Germany) was injected transrectally shortly prior to 59 
laparotomy. The first 12 patients enrolled received sextant injections (six injections into base, 60 
mid-portion, and apex of each prostatic lobe peripheral zone). The next 30 patients received 61 
injections into one of these sites: 1. prostate base bilaterally; 2. mid-portion bilaterally; 3. apex 62 
bilaterally; 4. left lobe (base, mid-portion, apex); or 5. right lobe (base, mid-portion, apex). A 63 
near-infrared-sensitive probe (Fluobeam®, Fluoptics, Grenoble, France) was used to collect 64 
fluorescence generated in the tissue under real-time image guidance. Independent of the findings 65 
of fluorescence SLN detection, an extended PLND was subsequently performed. An ex-vivo 66 
fluorescence examination of all dissected lymph nodes was then carried out. Lymphatic landing 67 
sites per anatomical region of the prostate were depicted graphically. Diagnostic statistics 68 
assessed the value of ICG in detecting lymph node metastases.  69 
 Baseline characteristics of the patients are summarized in Supplementary Table 1. All 42 70 
patients had one or more lymph nodes detected by fluorescence. The lymphatic mapping study 71 
showed that (Fig. 1 and Supplementary Table 2): 1. the external and internal iliac regions 72 
encompass the majority of SLNs; 2. the common iliac regions contain up to 22% of all SLNs; 3. a 73 
prostatic lobe can drain into the contralateral group of pelvic lymph nodes; 4. the fossa of 74 
Marcille also receives significant drainage; and 5. practically all sites of the prostate can drain to 75 
different regions of the pelvis bilaterally.  76 
Thus, the drainage pattern did not show that distinct lymphatic pathways exist per 77 
prostatic anatomical region. Our results also underscore crossover of lymphatics to the opposite 78 
side and that the common iliac regions and the fossa of Marcille should not be overlooked during 79 
PLND, as combined they may contain up to a third of all SLNs. The multitude of lymphatic 80 
landing sites as well as the individual variability of lymphatic drainage may represent an obstacle 81 
to intra-operative SLN detection. In contrast to breast cancer, in prostate cancer lymph node 82 
metastases do not follow a pre-defined pathway of metastatic spread and there is no certainty that 83 
the histologic status of the SLN reflects the status of the entire pelvic node basin.  84 
Among the 12 patients who received systematic ICG injections a median of 15 SLNs per 85 
patient were removed (IQR 10-20). Five patients had a total of 29 lymph node metastases (Table 86 
1). Of these, 16 were ICG-positive, yielding a sensitivity for the detection of lymph node 87 
metastases of 55%. The negative predictive value was 95%, the specificity was 57%, and the 88 
predictive positive value 8%. Repeating analyses with patients as unit of analysis showed that 89 
four of five patients had ICG-positive lymph node metastases, yielding a sensitivity for the 90 
correct staging of patients of 80%. 91 
Hruby et al evaluated 38 patients who underwent laparoscopic RP (4). The sensitivity of 92 
the SLN technique with ICG to detect metastases was 98% (42 nodes in 15 patients). Yuen et al 93 
reported on 66 patients who underwent RP and SNL detection using ICG (5). Only nine 94 
metastases in six patients were detected, all of which were ICG-positive. Our median number of 95 
nodes removed was 35 vs. 18 in both previous reports. These findings suggest that our template 96 
leads to a notably more complete PLND, which would result in more precise sensitivity analyses. 97 
In addition, our median number of SLNs removed was 15 (IQR 10-20), which is in the higher 98 
range of most previous studies using ICG alone or in combination with a radio-colloid (3–6). 99 
Other authors may not have searched as thoroughly for SLNs in surgically less accessible regions 100 
such as the proximal part of the common iliac vessels, in the fossa of Marcille and in the 101 
presacral regions. In Yuen et al’s study, only 2% and 1% of all SLNs were found in the common 102 
iliac and presacral regions, respectively (5).  103 
The low sensitivity of ICG to detect metastases in the current study raises the concern of 104 
skip metastases. The presence of tumor cells in the lymph nodes may clog the feeding lymphatics 105 
and interfere with their ability to take up ICG, as it has been postulated for radio-colloids (7). 106 
Interestingly, we could sometimes visualize that lymphatic drainage goes around enlarged nodes. 107 
Going forward, emerging molecular imaging modalities using dyes conjugated with tumor-108 
specific peptides may provide added sensitivity (8–10). It has to be noted that it is not possible to 109 
discriminate with certainty between primary landing sites and higher levels of drainage. 110 
However, the fact that fluorescent lymph nodes appeared 15-30 min after ICG injection and that 111 
direct drainage through lymphatic vessels could be seen in some cases suggests that these lymph 112 
nodes can be considered SLNs.  Our study is limited by its small sample size. Nevertheless, it 113 
included a high number of lymph node metastases in the setting of extended PLND, allowing 114 
appropriate sensitivity analyses.  115 
In conclusion, our lymphatic mapping study delineated a complex drainage pattern of the 116 
prostate that questions whether targeted lymph node dissection can be implemented in prostate 117 
cancer. Together with the low sensitivity for the detection of metastases, these results suggest that 118 
for the time being fluorescence SNL detection does not represent an alternative to a meticulously 119 
performed PLND in higher-risk patients.  120 
 121 
Conflicts of interest: the Fluobeam® imaging device was provided at no charge by Fluoptics. 122 
However, the authors had complete control of the data and information submitted for publication. 123 
 124 
 125 
 126 
Figure legend 127 
Fig. 1. Percentages of sentinel nodes detected per drainage region with regard to anatomical sites 128 
of the prostate. The ICG injection sites are depicted in the upper right corner. The orange zones 129 
represent the external iliac regions, the yellow zones the internal iliac regions, the green zones the 130 
common iliac regions, and the regions delineated by dashed lines the fossas of Marcille.  131 
 132 
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